differences exist among the three TNFα antagonists in terms of molecular structure, pharmacokinetics, interactions with TNFα, generation of antibodies, induction of apoptosis, and dosing regimen, switching from one anti-TNFα agent to another could represent an option in RA patients who fail or are intolerant to the first treatment (4) . Overall, the available data suggest that trying another anti-TNFα agent may result in improved disease control, although the published studies widely vary in respect of population size, study design and outcomes (Tab. I) . In this paper, we report the results of an ongoing, longitudinal, observational study evaluating the clinical response after switching from one anti-TNFα agent to another in patients with RA within a "real-life" clinical setting. In addition, a review of the literature was made.
PATIENTS AND METHODS
In this ongoing, longitudinal, observational study, we prospectively collected data since 2000 on efficacy and safety for patients starting biological treatments in our rheumatology unit.
INTRODUCTION
T he treatment of rheumatoid arthritis (RA) has evolved over the past decade with the introduction of anti-tumor necrosis factor (TNF) α agents, which allowed remarkable advances in controlling signs and symptoms of inflammation and in slowing joint destruction (1) (2) (3) . However, some patients do not respond or show suboptimal response to the currently available anti-TNFα agents (infliximab, etanercept, and adalimumab) used either as monotherapy or in combination with methotrexate. Furthermore, patients who respond initially may lose efficacy over time (4) or develop adverse events. Because significant The present analysis was restricted to patients with a diagnosis of RA who switched from one TNFα antagonist to another, with a minimum of 6 months' follow-up (at least 3 months for each treatment) by the end of December 2007. RA was classified according to the revised ACR criteria (27) . The choice of the biological agent was based on clinical considerations only; thus, these patients represent a 'real-life' sample of subjects undergoing TNFα antagonist treatment. Infliximab 3-5 mg/kg was administered intravenously at weeks 0-2-6, and every 6-8 weeks thereafter; etanercept (25 mg twice a week or 50 mg once weekly) and adalimumab (40 mg every fortnight) were given subcutaneously.
Clinical assessment
Each patient was evaluated by the same rheumatologist at baseline before starting TNFα antagonist, every 3 months, and at the last administration of the drug. Clinical and demographic data were collected into a standardized form previously described (28) . Clinical evaluation in RA patients included: swollen and tender joint count (0-28), patient and physician global assessment on a visual analogue scale (VAS, 0-100 mm), and Health Assessment Questionnaire (HAQ) (29) . Each patient underwent a blood drawing to evaluate erythrocyte sedimentation rate (ESR) and C reactive protein (CRP). Disease activity score (28 joint count, four variables, ESR-based; DAS28) was calculated and the clinical response (none, moderate, good) was evaluated according to the European League Against Rheumatism (EULAR) criteria (30) . In addition, we measured the clinical remission defined as a DAS28 score of less than 2.6 and low disease activity as a DAS28 score equal to or less than 3.2 (31). Drug discontinuation was based on the rheumatologist's opinion and the reason of withdrawal recorded as lack of efficacy (LaE) (patients who never reached a satisfactory response, i.e. primary failure), loss of efficacy (LoE) (patients who relapsed after an initial response, i.e. secondary failure), adverse events (AEs) or other.
The wash-out period between TNFα antagonists was 6 weeks.
Statistical analysis
Qualitative differences between subgroups were analysed by the chi-squared and Fisher's exact Table II shows the clinical and therapeutic features of the 22 patients (mean age 51.6 years, range 17-78; mean disease duration 8.4 years, range 3-22) who received first etanercept and then adalimumab. After 3 months of adalimumab all clinical parameters evaluated except ESR showed a significant improvement (Fig. 1) . The mean duration of adalimumab was longer than the previous etanercept treatment (16.4 vs 12.6 months, NS). Table II shows the clinical and therapeutic features of the 12 patients (mean age 45.1 years, range 33-64; mean disease duration 8.5 years, range 3-17) who received adalimumab as first drug and etanercept as second. After 3 months of etanercept physician global assessment, HAQ and all DAS28 components except swollen joints showed a significant improvement (Fig. 2) . The mean duration of etanercept was significantly longer than the previous adalimumab treatment (14.2 vs 8.8 months, p<0.05). Table II 
Switchers stratified by sequence of drug Switching from etanercept to adalimumab

Switching from adalimumab to etanercept
Switching from infliximab to etanercept
DISCUSSION
The findings of this longitudinal, observational, single center study on a selected population of RA patients confirm that the failure of a first anti-TNFα agent does not preclude the response to another. In addition, the probability of achieving a clinical response after the switching is higher in patients discontinuing the first treatment for secondary failure or adverse events in comparison with switchers for primary failure. TNFα inhibitors have significantly changed the therapeutic approach to RA patients: the three available agents -adalimumab, etanercept, infliximab -have proven highly efficacious, especially when used in combination with methotrexate (32) (33) (34) . Nevertheless, approximately one third of patients discontinue anti-TNFα treatment due to inefficacy or intolerance. Because the TNFα antagonists differ in chemical structure, mechanism of action and safety profile, there is a rationale for switching from one to another. Several reports, reviewed in Table I , support this possibility and switching to a different TNFα antagonist has now become a common practice in RA, although no published guidelines exist. Studies on switching among anti-TNFα agents are mostly limited by short trial duration, small sample size and lack of randomization or controls. Re- garding the reason for switching, it has rarely been specified whether the inefficacy was primary or secondary, and sometimes only selected groups of switchers have been considered. In addition, only few studies have included all the three available drugs (Tab. I).
The results from the earlier reports, mostly considering the switching between etanercept and infliximab, have shown that the response to the second drug, irrespective of the first one employed, may significantly ameliorate the outcome measures with a good safety profile (5-9). The subsequent availability of adalimumab offered a further opportunity in the practice of switching anti-TNFα agents, and led to sustain the previous findings reporting a good clinical response after the failure of the first treatment. Our data, in which all the three available TNFα antagonists were considered, confirm the beneficial effect of the second drug. Moreover, in our patients, both the clinical response and the treatment duration with the second anti-TNFα were more favourable when LoE or AEs, respect to LaE, caused the discontinuation of the first. As a matter of fact, only 38.4% of patients who never reached a satisfactory response with the first TNFα antagonist responded to the second, whereas higher percentages of patients showed a satisfactory response after discontinuing the first agent for secondary failure (66.7%) or adverse events (88.9%). Notably, 71.4% of patients who discontinued the second drug for LaE had stopped the first one for the same reason. These observations appear in agreement with some of the published reports. The ReAct analysis, performed in 899 patients who switched to adalimumab, demonstrated a better response rate in patients who replaced previous treatments for LoE and AEs than in those who presented primary failure (19) . Similarly, in a smaller study in which 18 patients were treated with etanercept after infliximab failure, the clinical improvement was higher in patients switching for LoE than in those experiencing LaE with the first agent, whereas patients who had withdrawn for AEs were not considered (17) . Recently, a report from the GISEA study group has shown that all the 37 RA patients who began etanercept after developing intolerance to infliximab reached a clinical response according to EULAR and ACR criteria (18) .
Finally, another open-label study on 41 patients who switched from infliximab to adalimumab confirmed a clinically meaningful improvement mostly in patients who had ceased the first treatment for LoE or AEs (24) . However, the issue of whether the reason for switching may influence the response to the other anti-TNFα has not still completely defined. Indeed, a recent study yielded a different conclusion: the clinical response to a second anti-TNFα agent was irrespective of the reason for stopping the prior treatment, although a better outcome was admitted in patients showing primary inefficacy with the first drug (20) . In our patients, the mean treatment duration with the second anti-TNFα was significantly longer than with the first one.
Our results concur with those emerging from a Danish national register of biological treatments, where the survival of the second anti-TNFα in RA patients was longer than the first (22) . Conversely, the analysis of the national Spanish register showed a reduction in the survival of the second anti-TNFα agent, although it was longer in patients who switched for AEs (13) . There are some limitations to our study. First, the observational design with no randomisation of treatment options. Second, being a "real-life study", the decision to replace one TNFα antagonist with another depended merely on the treating physician's judgement. However, our data, based on the application of the EULAR response criteria, on the whole support the possibility of trying another anti-TNFα in RA patients failing the first place treatment.
In conclusion, the results of this study suggest that RA patients may be successfully treated with another TNFα antagonist especially those withdrawing for secondary failure or adverse events. Conversely, for patients stopping anti-TNFα treatment due to primary failure, different biological drugs, such as rituximab and abatacept, might offer a greater chance of therapeutic success.
